The California Aspen Dental settlement announcement is a buyer-side warning for dental service organization rollups: the management agreement is not back-office paperwork if it controls clinical economics, advertising, and patient-facing decisions. Knowing how to read the documents before signing is the difference between a clean acquisition and an inherited enforcement posture.
By Noah Green CPA CFE
This article is for general diligence education. It is not legal advice, investment advice, tax advice, or a conclusion about any specific transaction. The California Attorney General announced a settlement on May 7, 2026. The AG release states the settlement is subject to court approval. Current approval status and the full terms of any filed consent judgment should be verified before publication or reliance on this article.
The Short Version
California alleged Aspen Dental Management went beyond administrative support and interfered with ownership and management of dentistry. The state also alleged clinician sales incentives and misleading advertising. The AG release announced \$2 million in penalties, a \$300,000 restitution fund, and injunctive conduct limits, all subject to court approval.
For buyers and investors, the core issue is not whether a dental service organization can provide management services. The issue is whether the specific rights and practices in the management services agreement cross from support into control. That question belongs in diligence, not in post-close remediation.
For the broader PE healthcare checklist, see the private equity healthcare rollup diligence guide and the sibling USAP antitrust case study.
Public Posture
The California Attorney General announced the Aspen Dental settlement on May 7, 2026 through the official California Department of Justice release linked in Primary Sources below. The AG release describes \$2 million in penalties, a \$300,000 restitution fund, and injunctive limits touching ownership control, revenue-linked fees, clinician sales incentives, advertising disclosures, and noncompetes.
The critical posture limit is stated in the AG release itself: the settlement was subject to court approval as of the announcement date. The filed consent judgment, if approved, may contain terms, definitions, or compliance obligations that go beyond what the press release summarizes. Any buyer, investor, or lender relying on this matter for diligence purposes should pull the actual court filing, confirm approval status, and read the operative injunctive language rather than relying on the release summary alone.
The California AG brought this matter under California corporate practice of dentistry restrictions, the California Unfair Competition Law, and false advertising theories. Those are state-law theories, but the underlying structural questions they address — who controls clinical decisions, how clinicians are compensated, and what patients are told — are not unique to California. Similar restrictions exist in most states, and the specific language varies enough that a DSO operating across multiple states needs a state-by-state legal review of its management services agreements, not a single national template.
The Mechanism Regulators Alleged
The alleged mechanism was a DSO crossing from support into control. The California AG alleged Aspen provided management, staffing, advertising, office buildout, equipment, and practice support, but exceeded a business-support role and interfered with ownership and management of dentistry. The AG also alleged the use of clinician sales incentives and misleading advertising.
To understand why this matters structurally, it helps to understand how the DSO model is supposed to work under corporate practice of dentistry doctrine. In most states, a non-dentist entity cannot own a dental practice, employ dentists to provide clinical services, or direct clinical judgment. The DSO model is designed to work around that restriction by separating the business functions — real estate, equipment, billing, marketing, staffing support, and administrative services — from the clinical functions, which remain with a dentist-owned professional entity.
The management services agreement is the document that defines that boundary. A well-drafted MSA gives the management company rights over business operations and leaves clinical decisions with the licensed dentist. The alleged problem in the Aspen matter, as described in the AG release, is that the actual practice went beyond what a support role permits. The AG alleged interference with ownership and management of dentistry, which is the core of the corporate practice prohibition.
The second alleged mechanism was clinician sales incentives. If a dentist’s compensation is tied to production volume, treatment plan acceptance rates, or revenue targets in a way that rewards recommending treatment regardless of clinical need, that creates a conflict between the clinician’s financial interest and the patient’s clinical interest. Regulators in multiple states have treated production-based incentives as evidence that the management company is directing clinical judgment.
The third alleged mechanism was misleading advertising. The AG release references advertising disclosures as part of the injunctive relief, which suggests the state alleged that patient-facing advertising about pricing, insurance acceptance, discounts, or availability was not adequately substantiated or was misleading.
Together, these three alleged mechanisms — control over ownership and management, clinician sales incentives, and misleading advertising — describe a pattern that buyers should test in any DSO acquisition, regardless of brand or geography.
Warning Signs for Buyers
The following are observable indicators that a DSO target may have a clinical-control problem. None of these is conclusive on its own, but each one warrants a follow-up document request and a legal opinion before closing.
- The management company controls pricing decisions, refund approvals, treatment plan presentation scripts, or patient financing terms without dentist-owner sign-off.
- Management fees are calculated as a percentage of gross revenue or net collections in a way that creates a direct financial incentive for the management company to push higher-revenue treatment.
- Dentist-owner governance rights exist in the MSA but are not reflected in actual workflows. The dentist signs off on paper but the management company runs the office.
- Clinician compensation plans include production bonuses, case-acceptance bonuses, or daily production targets that reward recommending treatment regardless of clinical necessity.
- Office performance dashboards or daily production reports are shared with management company personnel and used in clinician performance reviews.
- Call-center scripts or patient-facing intake materials include representations about pricing, insurance acceptance, Medicaid participation, discounts, or appointment availability that have not been reviewed for accuracy and substantiation.
- Noncompete agreements restrict dentist-owners from practicing independently in a way that limits their ability to exit the management relationship.
- The MSA contains termination provisions that effectively give the management company control over the practice’s patient records, equipment, or lease in a way that makes exit impractical.
- The management company has made representations to lenders or investors about the practice’s revenue that depend on maintaining the current incentive structure.
- Prior state dental board complaints, patient complaints, or insurance audits have not been disclosed in the data room.
SPP has made the same structural point in franchise diligence: read The FTC Franchise Rule guide before relying on disclosure labels, and read the Burgerim case study for why labels do not replace operating evidence. The DSO context is different legally, but the diligence discipline is the same: the label on the agreement does not determine the legal or regulatory risk. The actual rights and practices do.
Diligence Tests Before Signing or Before the Wire
The following tests are organized by document category. Each test is designed to surface a specific risk before it becomes a post-close problem.
Management Services Agreement Review
Pull the current MSA and any amendments. Map every right the management company holds against the corporate practice of dentistry rules in each state where the target operates. Do not use a single national legal opinion. Get a state-specific opinion for each material jurisdiction. Pay particular attention to provisions covering pricing authority, treatment plan presentation, staffing decisions, marketing approval, and termination rights over practice assets.
Ask whether the MSA has been reviewed by state dental board counsel or outside healthcare regulatory counsel in the last three years. If not, that is a gap.
Responsibility Matrix
Build a written responsibility matrix that assigns each operational decision to either the management company or the dentist-owner. Cover at minimum: clinical treatment decisions, treatment plan pricing, patient refund approvals, hiring and firing of clinical staff, scheduling, supply purchasing, marketing content approval, insurance credentialing, and patient complaint resolution.
Compare the written control structure to actual workflows by interviewing office managers and dentist-owners separately. If the answers differ, the paper structure does not reflect reality.
Revenue-Based Fee Reconciliation
Pull the fee schedule from the MSA and calculate the effective management fee as a percentage of gross collections for the last three years. Compare that rate to published guidance from state dental boards or healthcare regulatory counsel on permissible fee structures. In some states, a percentage-of-revenue fee is itself a red flag for corporate practice concerns regardless of how the MSA labels it.
Reconcile the fee to the target’s financial statements. If the management fee has grown faster than revenue, ask why.
Clinician Incentive Plan Review
Request all clinician compensation plans, bonus schedules, production reports, and performance review templates for the last three years. Look for any metric that ties compensation to treatment plan acceptance rates, case volume, or revenue targets. Ask whether those metrics are shared with management company personnel and whether they are used in performance reviews.
If production bonuses exist, ask for the legal opinion supporting their compliance with state dental board rules. If no opinion exists, commission one before closing.
Advertising Substantiation Review
Pull all patient-facing advertising materials, website content, social media posts, direct mail, and call-center scripts for the last two years. For each claim about pricing, discounts, insurance acceptance, Medicaid participation, appointment availability, or quality of care, ask for the substantiation. Unsubstantiated claims are a California Unfair Competition Law exposure and a potential FTC Act exposure in other contexts.
Check whether the target has received any cease-and-desist letters, state AG inquiries, or dental board complaints related to advertising.
Patient Refund and Complaint Records
Request all patient refund records, complaint logs, and insurance dispute records for the last three years. A pattern of refund denials or unresolved patient complaints about billing is a signal that the patient-facing economics may be a problem.
Check whether the \$300,000 restitution fund described in the Aspen AG release gives any indication of the types of patient harm alleged. The AG release does not detail the specific refund categories, but the existence of a restitution fund means patient-level financial harm was part of the state’s theory.
Noncompete and Exit Rights Review
Review all noncompete agreements with dentist-owners and employed dentists. Assess enforceability under state law and whether the restrictions are consistent with state dental board guidance on dentist independence. In California, noncompetes for employees are generally unenforceable under Business and Professions Code Section 16600, but the analysis differs for business sale contexts and varies by state.
Review MSA termination provisions to determine whether the management company retains control over patient records, equipment, or the practice lease after termination. If exit is practically impossible, the dentist-owner’s independence is limited regardless of what the MSA says about clinical authority.
Regulatory and Litigation History
Run a full regulatory history check: state dental board disciplinary records, state AG inquiries, CID history, insurance audit findings, and any prior litigation involving the management company or its affiliated practices. Check PACER for federal litigation and the relevant state court dockets for state litigation.
Ask the seller to represent and warrant in the purchase agreement that no regulatory inquiries, dental board complaints, or state AG contacts are pending or threatened. Negotiate a specific indemnity for pre-close regulatory conduct.
How to Read the California AG Release
The AG release is a press release, not the operative legal document. It summarizes the state’s allegations and the agreed relief, but it does not contain the full factual record, the specific injunctive language, or the compliance monitoring terms.
When the consent judgment is filed and approved, pull the actual court document. Read the injunctive provisions carefully. The specific definitions of prohibited conduct — what counts as interfering with ownership and management of dentistry, what fee structures are prohibited, what advertising disclosures are required — will be in the consent judgment, not the press release.
The injunctive terms in a consent judgment also function as a public statement of what the regulator considers the legal boundary. Even if your target is not Aspen Dental, the consent judgment’s definitions of prohibited conduct describe the California AG’s current enforcement posture on DSO clinical control. That is useful diligence context for any California DSO acquisition.
The \$2 million penalty and \$300,000 restitution fund are the monetary terms. The conduct limits are the more durable risk signal. Injunctive relief in a state AG settlement typically runs for a defined period — often three to five years — and may include compliance reporting, monitoring, or audit rights. Check whether the consent judgment creates ongoing compliance obligations that would transfer to a buyer or affect the target’s operations post-close.
By the Numbers
| Data Point | Public Source Fact | Buyer Diligence Meaning |
|---|---|---|
| Announcement date | California AG announced settlement May 7, 2026 | Current court approval status must be verified before publication or reliance. The filed consent judgment may contain terms beyond the press release summary. |
| Penalties | \$2 million in penalties announced | Monetary relief at this scale can follow alleged clinical-control and advertising issues in a single-state action. Multi-state exposure would multiply the risk. |
| Restitution | \$300,000 restitution fund announced | Patient-facing economics, refund practices, and billing representations belong in diligence. A restitution fund signals patient-level financial harm was part of the state’s theory. |
| Conduct limits | Injunctive limits include ownership control, revenue-linked fees, clinician sales incentives, advertising disclosures, and noncompetes | The MSA, incentive plans, advertising materials, and noncompete agreements are core diligence documents, not ancillary contracts. |
| Transaction model | DSO providing management, staffing, advertising, office buildout, equipment, and practice support | Support services can create control risk depending on the specific rights granted and the actual operating practice. The label does not determine the risk. |
| Legal theories | California corporate practice of dentistry restrictions, California Unfair Competition Law, false advertising | These are state-law theories. Similar restrictions exist in most states. A multi-state DSO needs a state-by-state legal review, not a single national template. |
| Posture limit | Settlement subject to court approval as of AG release | Do not treat the AG release as the final word. Pull the consent judgment, confirm approval, and read the operative injunctive language. |
Source footer: Figures and posture are drawn from the public primary sources listed below. Dollar amounts and posture reflect the California AG release dated May 7, 2026. Court approval status should be independently verified.
Buyer / Investor Takeaway
A DSO buyer should not stop at asking whether the dentist owns the practice. The corporate practice of dentistry doctrine requires dentist ownership, but ownership on paper does not resolve the clinical-control question. The question is who actually controls the money, the messaging, the staffing, the incentives, the refunds, and the patient experience.
If the management company controls pricing, the management company is directing clinical economics. If clinician bonuses are tied to treatment plan acceptance, the management company is influencing clinical recommendations. If advertising claims are not substantiated, the management company is creating regulatory exposure for the dentist-owner and for any buyer who inherits the relationship.
The Aspen matter is also a reminder that the regulatory risk in a DSO acquisition is not limited to the management company. The dentist-owned professional entities are the licensed parties. A state dental board action or AG enforcement action can affect the licenses that the entire business depends on. Buyer diligence needs to cover both the management company and the professional entities.
For investors evaluating a PE-backed DSO platform, the same analysis applies at the portfolio level. If the platform’s management services agreement template has not been reviewed for compliance with corporate practice of dentistry rules in each operating state, that is a portfolio-level risk, not just a single-practice risk. A single AG action in one state can trigger regulatory scrutiny in other states, particularly if the management agreement template is uniform across the platform.
The practical pre-wire test is this: before the wire goes out, the buyer should be able to answer the following questions with document support. Who approves treatment plan pricing? Who approves patient refunds? What metrics are used in clinician performance reviews, and who sets them? What advertising claims have been made in the last two years, and what substantiation exists? Have any state dental board complaints, AG inquiries, or insurance audits been received in the last three years? If any of those questions cannot be answered with documents in hand, the wire should wait.
Related draft: Patient Care America FCA case study.
SPP Bottom Line
The Aspen Dental matter is a concrete example of what happens when a DSO’s paper structure and actual operating practice diverge. The California AG alleged that the management company went beyond support and into control, that clinician incentives were tied to sales volume, and that advertising was misleading. The state obtained monetary and conduct relief, subject to court approval.
For buyers, the takeaway is not that DSO acquisitions are off-limits. The takeaway is that the diligence work has to put legal structure and operating reality in the same room. The MSA has to be read against state corporate practice rules. The incentive plans have to be reviewed for clinical-independence concerns. The advertising has to be substantiated. The dentist-owner governance rights have to be tested against actual workflows.
A DSO that passes those tests is a different asset than one that does not. The diligence work is what tells you which one you are buying.